Figure 2. Comparison of OS and PFS, according to treatment line (A andB respectively) or platinum sensitivity (C and D respectively), between patients treated with a PLD-containing regimen vs. any other PLD-free schedule. Abbreviation: OS, overall survival; PFS, progression free survival; HR, hazard ratio; CPLD, carboplatin and pegylated liposomal doxorubicin; CP, carboplatin and paclitaxel; PLD pegylated liposomal doxorubicin; O, olaparib; C, carboplatin; G, gemcitabine; T, topotecan.